Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
The manufacturing conditions of Erbitux biosimilar from the CHO stable cell line need to be optimized by clients.
The cheapest research grade cetuximab biosimilar protein (1 mg for >$30) is also available.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Cetuximab (trade name Erbitux, Bristol-Myers Squibb and Eli Lilly and Company in US and Merck KGaA in Europe), a chimeric (mouse/human) anti-EGFR monoclonal antibody, is an EGFR inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab binds to EGFR and turns off the uncontrolled growth in cancers with EGFR mutations.
Cetuximab can be used for treatment of KRAS wild type colon cancer but has little or no effect in colorectal tumors harboring a KRAS mutation. Before treatment using Erbitux, it is better to do a diagnosis using the real time PCR companion diagnostic test for KRAS, the therascreen KRAS test.
There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1; HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, EGFR (epidermal growth factor receptor) located on cell surface sends a signal down the MAPK pathway that includes another protein, KRAS (also spelled K-ras). Mutations affecting EGFR and/or KRAS expression or activity could result in cancer. The mutated KRAS continuously sends a growth signal to the downstream pathway, leading to uncontrollable cell division, even if EGFR has been blocked.
C002: Erbitux Biosimilar Stable Cell Line (CHO)
The yield of Erbitux biosimilar from the CHO stable cell line was above 1.7 g/L in a 750 liter manufacturing.
The Erbitux biosimilar stable cell line alone can be transferred alone or together with the technology of process development and/or antibody purification.
Syd Labs also provides the following anti-ErbB/HER antibody biosimilar stable cell lines:
Vectibix Biosimilar Stable Cell Line (HER1, ErbB-1, EGFR)
Herceptin Biosimilar Stable Cell Line (HER2, ErbB-2, c-neu)
Perjeta / Omnitarg Biosimilar Stable Cell Line (HER2, ErbB-2, c-neu)
Copyright © 2009-2022 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.